Ind are not significant, they are necessary to begin a trial and by judging Nox performance on starting phase one trial I have no doubt you will be able to notch up another one. But equally judging on past performance and promised milestones the companies ability to follow through to a phase II trial is woeful. Why because they are undisciplined and keep changing priority, or according to your own presentations horses. Would you like me to give you a blow by blow of company presentation quotes that have never eventuated thus far or changed focus.
Ann: FDA allows Veyonda Pre-IND Submission for COVID-19, page-16
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.8¢ |
Change
-0.017(14.8%) |
Mkt cap ! $28.63M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 9.8¢ | $70.79K | 680.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 25356 | 9.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 240399 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |